{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:23:03Z","timestamp":1790486583090,"version":"4.1.0"},"reference-count":47,"publisher":"Cambridge University Press (CUP)","issue":"S12","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":2867,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2007]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Attention-deficit\/hyperactivity disorder (ADHD) is an impairing but usually treatable condition. Popular culture propagates the myth that ADHD recedes with age; this is not the case. Although it is common, &lt;20% of adults with ADHD are diagnosed or treated. Adults with ADHD show significant comorbidities with depressive  disorders, anxiety disorders, substance use, oppositional defiant disorder, personality disorders, sleep problems, and learning disabilities. However, symptoms that result from ADHD, such as mood symptoms or lability, are often mistaken for comorbid disorders. Comorbidity with ADHD impacts treatment compliance, treatment response, and patient insight. Insufficient data on the interaction between ADHD and comorbidities impedes proper diagnosis and treatment. Better clinical tools for assessing these conditions are needed. Food and Drug Administration-approved pharmacologic treatments for adult ADHD include stimulants, dexmethylphenidate, and the nonstimulant atomoxetine. Effect  sizes of approved medicines at approved doses are half those seen in children. Adults may also need longer duration of medication effects than children. Short-acting stimulants are likely to result in poorer adherence and have a higher risk for diversion or abuse. Risk of abuse is a major concern; stimulant treatments are controlled substances, and children with ADHD show increased risk of substance abuse. Psychosocial interventions may be beneficial in treating both ADHD and comorbidities.<\/jats:p><jats:p>In this expert roundtable supplement, Margaret Weiss, MD, PhD, presents a  comprehensive overview of complications surrounding differential diagnosis in adults with ADHD. Next, Mark A. Stein, PhD, reviews evaluation, comorbidity, and development of a treatment plan in this population. Finally, Jeffrey H. Newcorn, MD, provides a discussion on the pharmacologic options available for adults with ADHD, considering dosages specific to adults and common comorbidities.<\/jats:p>","DOI":"10.1017\/s1092852900026158","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:57:48Z","timestamp":1470099468000},"page":"1-16","source":"Crossref","is-referenced-by-count":52,"title":["The Complexity of ADHD: Diagnosis and Treatment of the Adult Patient With Comorbidities"],"prefix":"10.1017","volume":"12","author":[{"given":"Jeffrey H.","family":"Newcorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900026158_ref047","volume-title":"J Am Acad Child Adolesc Psychiatry","author":"Geller"},{"key":"S1092852900026158_ref022","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-006-0041-z"},{"key":"S1092852900026158_ref018","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291705006410"},{"key":"S1092852900026158_ref036","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.160.1.82"},{"key":"S1092852900026158_ref017","volume-title":"Williams JBW. SCID-I, Clinician Version","author":"First","year":"1997"},{"key":"S1092852900026158_ref040","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01671-2"},{"key":"S1092852900026158_ref020","volume-title":"Driven to Distraction","author":"Hallowell","year":"1994"},{"key":"S1092852900026158_ref023","doi-asserted-by":"publisher","DOI":"10.1016\/j.brat.2004.07.001"},{"key":"S1092852900026158_ref016","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0412"},{"key":"S1092852900026158_ref014","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-006-1006-2"},{"key":"S1092852900026158_ref004","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1176\/ajp.150.12.1792","article-title":"Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder","volume":"150","author":"Biederman","year":"1993","journal-title":"Am J Psychiatry"},{"key":"S1092852900026158_ref034","first-page":"594","volume-title":"A Handbook for Diagnosis and Treatment","author":"Barkley","year":"1998"},{"key":"S1092852900026158_ref012","doi-asserted-by":"publisher","DOI":"10.1037\/0894-4105.21.2.263"},{"key":"S1092852900026158_ref027","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900013687"},{"key":"S1092852900026158_ref011","volume-title":"Scattered Minds","author":"Adler","year":"2006"},{"key":"S1092852900026158_ref024","first-page":"752","article-title":"Adolescents with ADHD: patterns of behavioral adjustment, academic functioning, and treatment utilization","volume":"30","author":"Barkley","year":"1991","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"S1092852900026158_ref002","volume-title":"Canadian Attention Deficit Disorder Resource Alliance. Canadian Practice Guidelines for ADHD","year":"2006"},{"key":"S1092852900026158_ref001","volume-title":"Adult ADHD NOS: Is it a valid diosrder?","author":"Faraone","year":"2005"},{"key":"S1092852900026158_ref005","doi-asserted-by":"publisher","DOI":"10.1080\/10550490591003639"},{"key":"S1092852900026158_ref015","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsm005"},{"key":"S1092852900026158_ref013","doi-asserted-by":"publisher","DOI":"10.1037\/0893-164X.17.2.151"},{"key":"S1092852900026158_ref019","volume-title":"Manual for the Adult Self Report Inventory and Adult Symptom Inventory","author":"Gadow","year":"2004"},{"key":"S1092852900026158_ref041","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0304"},{"key":"S1092852900026158_ref006","doi-asserted-by":"publisher","DOI":"10.1016\/0010-440X(90)90026-O"},{"key":"S1092852900026158_ref025","first-page":"1","article-title":"Diagnosis and treatment of adults with attention-deficit\/hyperactivity disorder","volume":"12","author":"Biederman","year":"2007","journal-title":"CNS Spectr"},{"key":"S1092852900026158_ref008","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-3289(96)90139-X"},{"key":"S1092852900026158_ref042","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.10.3.286"},{"key":"S1092852900026158_ref007","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-2-9"},{"key":"S1092852900026158_ref010","doi-asserted-by":"publisher","DOI":"10.1017\/S0954579406060512"},{"key":"S1092852900026158_ref026","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519080-00001"},{"key":"S1092852900026158_ref028","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.07.032"},{"key":"S1092852900026158_ref039","unstructured":"Strattera TM [package insert]. Indianapolis, IN: Eli Lilly and Company; 2002."},{"key":"S1092852900026158_ref030","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.01.027"},{"key":"S1092852900026158_ref044","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300593"},{"key":"S1092852900026158_ref029","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.11.043"},{"key":"S1092852900026158_ref046","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000155320.52322.37"},{"key":"S1092852900026158_ref031","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200104000-00015"},{"key":"S1092852900026158_ref032","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.02.008"},{"key":"S1092852900026158_ref021","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199105000-00005"},{"key":"S1092852900026158_ref045","volume-title":"Abuse liability of intravenous L-lysine-damphetamine (LDX)","author":"Jasinski","year":"2006"},{"key":"S1092852900026158_ref003","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.4.716"},{"key":"S1092852900026158_ref033","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2000.10.311"},{"key":"S1092852900026158_ref035","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.09.011"},{"key":"S1092852900026158_ref037","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.4.883"},{"key":"S1092852900026158_ref038","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666050-00006"},{"key":"S1092852900026158_ref009","first-page":"1","article-title":"Comorbid psychiatric disorders in adults with ADHD","volume":"15","author":"Barkley","year":"2007","journal-title":"The ADHD Report"},{"key":"S1092852900026158_ref043","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200404000-00008"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900026158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T15:04:23Z","timestamp":1556809463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900026158\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":47,"journal-issue":{"issue":"S12","published-print":{"date-parts":[[2007]]}},"alternative-id":["S1092852900026158"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900026158","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007]]}}}